CoChat
Sign Up
Cited by 117Angiogenesis and VEGF in CancerCancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment

Open access
Hu, Haoyue, Chen, Yue, Tan, Songtao, Wu, Silin, Huang, Yan, Fu, Shengya, Luo, Feng, He, Jun·2022·Frontiers in Immunology
DOI 10.3389/fimmu.2022.802846PMC PMC8905241
Open this paper in CoChat — free accountOpen PDF

Abstract

Anti-angiogenesis therapy, a promising strategy against cancer progression, is limited by drug-resistance, which could be attributed to changes within the tumor microenvironment. Studies have increasingly shown that combining anti-angiogenesis drugs with immunotherapy synergistically inhibits tumor growth and progression. Combination of anti-angiogenesis therapy and immunotherapy are well-established therapeutic options among solid tumors, such as non-small cell lung cancer, hepatic cell carcinoma, and renal cell carcinoma. However, this combination has achieved an unsatisfactory effect among some tumors, such as breast cancer, glioblastoma, and pancreatic ductal adenocarcinoma. Therefore, resistance to anti-angiogenesis agents, as well as a lack of biomarkers, remains a challenge. In this review, the current anti-angiogenesis therapies and corresponding drug-resistance, the relationship between tumor microenvironment and immunotherapy, and the latest progress on the combination of both therapeutic modalities are discussed. The aim of this review is to discuss whether the combination of anti-angiogenesis therapy and immunotherapy can exert synergistic antitumor effects, which can provide a basis to exploring new targets and developing more advanced strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2022.802846

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Acquired resistance to anti-angiogenic agents is frequent due to compensatory pro-angiogenic signaling and hypoxia-induced modulation of cancer cell signaling.

    “Thus, acquired resistance is frequently observed, due to the activation of compensatory pro-angiogenic signaling pathways and hypoxia-induced modulation of cancer cell signaling [34].”

    From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [34]

    In “The Resistance to Antiangiogenic Therapy” (page unavailable), the review identifies acquired resistance as a cause of treatment failure and links angiogenesis-related gene-expression changes and c-Met overexpression to resistance. “Tumor Microenvironment and Antiangiogenic Therapy” (page unavailable) says treatment can aggravate hypoxia and that hypoxia-induced HIF-1α can drive tumor-cell changes underlying resistance. The copy does not establish that acquired resistance is frequent specifically because compensatory pro-angiogenic pathways are activated; it describes the mechanisms more narrowly. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 82

  1. [4]Pàez-Ribes M Allen E Hudock J Takeda T Okuyama H Viñals F. Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell (2009) 15(3): 220–31. doi: 10.1016/j.ccr.2009.01.027 PMC2874829 19249680 · DOI
  2. [5]Kindler HL Niedzwiecki D Hollis D Sutherland S Schrag D Hurwitz H. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (Calgb 80303). J Clin Oncol (2010) 28(22): 3617. doi: 10.1200/JCO.2010.28.1386 20606091 PMC2917317 · DOI
  3. [6]Keunen O Johansson M Oudin A Sanzey M Rahim SAA Fack F. Anti-Vegf Treatment Reduces Blood Supply and Increases Tumor Cell Invasion in Glioblastoma. Proc Natl Acad Sci (2011) 108(9): 3749–54. doi: 10.1073/pnas.1014480108 PMC3048093 21321221 · DOI
  4. [7]Ebos JM Lee CR Cruz-Munoz W Bjarnason GA Christensen JG Kerbel RS. Accelerated Metastasis After Short-Term Treatment With a Potent Inhibitor of Tumor Angiogenesis. Cancer Cell (2009) 15(3): 232–9. doi: 10.1016/j.ccr.2009.01.021 PMC4540346 19249681 · DOI
  5. [8]Ramadan W Zaher D Altaie A Talaat I Elmoselhi A. Potential Therapeutic Strategies for Lung and Breast Cancers Through Understanding the Anti-Angiogenesis Resistance Mechanisms. Int J Mol Sci (2020) 21(2): 565. doi: 10.3390/ijms21020565 PMC7014257 31952335 · DOI
  6. [9]Missiaen R Mazzone M Bergers G. The Reciprocal Function and Regulation of Tumor Vessels and Immune Cells Offers New Therapeutic Opportunities in Cancer. Semin Cancer Biol (2018) 52: 107–16. doi: 10.1016/j.semcancer.2018.06.002 PMC6548870 29935312 · DOI
  7. [10]Craven K Gore J Korc M. Overview of Pre-Clinical and Clinical Studies Targeting Angiogenesis in Pancreatic Ductal Adenocarcinoma. Cancer Lett (2016) 381(1): 201–10. doi: 10.1016/j.canlet.2015.11.047 PMC4919237 26723874 · DOI
  8. [11]Ioannidou E Moschetta M Shah S Parker J Ozturk M Pappas-Gogos G. Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets. Int J Mol Sci (2021) 22(18): 9926. doi: 10.3390/ijms22189926 34576107 PMC8472415 · DOI
  9. [12]Kerbel R. Reappraising Antiangiogenic Therapy for Breast Cancer. Breast (Edinburgh Scotland) (2011) 20 Suppl 3(0 3): S56–60. doi: 10.1016/s0960-9776(11)70295-8 PMC4540338 22015294 · DOI
  10. [13]Ahir B Engelhard H Lakka S. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. Mol Neurobiol (2020) 57(5): 2461–78. doi: 10.1007/s12035-020-01892-8 PMC7170819 32152825 · DOI
  11. [14]Cascone T Herynk M Xu L Du Z Kadara H Nilsson M. Upregulated Stromal Egfr and Vascular Remodeling in Mouse Xenograft Models of Angiogenesis Inhibitor-Resistant Human Lung Adenocarcinoma. J Clin Invest (2011) 121(4): 1313–28. doi: 10.1172/jci42405 PMC3070607 21436589 · DOI
  12. [15]Huijbers E van Beijnum J Thijssen V Sabrkhany S Nowak-Sliwinska P Griffioen A. Role of the Tumor Stroma in Resistance to Anti-Angiogenic Therapy. Drug Resist Updat: Rev Comment Antimicrob Anticancer Chemother (2016) 25: 26– 37. doi: 10.1016/j.drup.2016.02.002 27155374 · DOI
  13. [16]Chandra A Rick J Yagnik G Aghi MK. Autophagy as a Mechanism for Anti-Angiogenic Therapy Resistance. Semin Cancer Biol (2020) 66: 75– 88. doi: 10.1016/j.semcancer.2019.08.031 31472232 PMC7047534 · DOI
  14. [17]Li C Teixeira A Zhu H Ten Dijke P. Cancer Associated-Fibroblast-Derived Exosomes in Cancer Progression. Mol Cancer (2021) 20(1): 154. doi: 10.1186/s12943-021-01463-y 34852849 PMC8638446 · DOI
  15. [18]Mao X Xu J Wang W Liang C Hua J Liu J. Crosstalk Between Cancer-Associated Fibroblasts and Immune Cells in the Tumor Microenvironment: New Findings and Future Perspectives. Mol Cancer (2021) 20(1): 131. doi: 10.1186/s12943-021-01428-1 34635121 PMC8504100 · DOI · Paper page
  16. [19]Deepak K Vempati R Nagaraju G Dasari V Nagini S Rao D. S N Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer. Pharmacol Res (2020) 153: 104683. doi: 10.1016/j.phrs.2020.104683 32050092 · DOI
  17. [20]Zhang H Wang Z Peng Q Liu Y-Y Zhang W Wu L. Tumor Refractoriness to Endostatin Anti-Angiogenesis Is Associated With the Recruitment of Cd11b+ Gr1+ Myeloid Cells and Inflammatory Cytokines. Tumori J (2013) 99(6): 723–33. doi: 10.1700/1390.15462 24503797 · DOI
  18. [21]Wang Z Li Z Wang Y Cao D Wang X Jiang M. Versican Silencing Improves the Antitumor Efficacy of Endostatin by Alleviating Its Induced Inflammatory and Immunosuppressive Changes in the Tumor Microenvironment. Oncol Rep (2015) 33(6): 2981–91. doi: 10.3892/or.2015.3903 25872924 · DOI
  19. [22]Wang L Wang J Li Z Liu Y Jiang M Li Y. Silencing Stem Cell Factor Attenuates Stemness and Inhibits Migration of Cancer Stem Cells Derived From Lewis Lung Carcinoma Cells. Tumor Biol (2016) 37(6): 7213–27. doi: 10.1007/s13277-015-4577-6 26666817 · DOI
  20. [23]Wang L Guo H Lin C Yang L Wang X. Enrichment and Characterization of Cancer Stem−Like Cells From a Cervical Cancer Cell Line. Mol Med Rep (2014) 9(6): 2117–23. doi: 10.3892/mmr.2014.2063 PMC4055449 24676900 · DOI
  21. [24]Lin C Wang L Wang H Yang L Guo H Wang X. Tanshinone Iia Inhibits Breast Cancer Stem Cells Growth In Vitro and In Vivo Through Attenuation of Il-6/Stat3/Nf-Kb Signaling Pathways. J Cell Biochem (2013) 114(9): 2061–70. doi: 10.1002/jcb.24553 23553622 · DOI
  22. [25]Cao L Fan X Jing W Liang Y Chen R Liu Y. Osteopontin Promotes a Cancer Stem Cell-Like Phenotype in Hepatocellular Carcinoma Cells Via an Integrin–Nf-κb–Hif-1α Pathway. Oncotarget (2015) 6(9): 6627. doi: 10.18632/oncotarget.3113 25749383 PMC4466639 · DOI
  23. [26]Santoyo-Ramos P Likhatcheva M García-Zepeda EA Castañeda-Patlán MC Robles-Flores M. Hypoxia-Inducible Factors Modulate the Stemness and Malignancy of Colon Cancer Cells by Playing Opposite Roles in Canonical Wnt Signaling. PloS One (2014) 9(11): e112580. doi: 10.1371/journal.pone.0112580 25396735 PMC4232394 · DOI
  24. [27]Zhang L Huang R Shen Y Liu J Wu Y Jin J. Viaenhanced Anti-Tumor Efficacy by Inhibiting Hif-1α to Reprogram Tams Core-Satellite Upconverting Nanoparticles With Curcumin Mediated Photodynamic Therapy. Biomater Sci (2021) 9: 6403–15. doi: 10.1039/d1bm00675d 34259235 · DOI
  25. [28]Zahavi D Weiner L. Tumor Mechanisms of Resistance to Immune Attack. Prog Mol Biol Trans Sci (2019) 164: 61– 100. doi: 10.1016/bs.pmbts.2019.03.009 31383409 · DOI
  26. [29]Whiteside T. Immune Suppression in Cancer: Effects on Immune Cells, Mechanisms and Future Therapeutic Intervention. Semin Cancer Biol (2006) 16(1): 3– 15. doi: 10.1016/j.semcancer.2005.07.008 16153857 · DOI
  27. [30]Finke JH Rini B Ireland J Rayman P Richmond A Golshayan A. Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients. Clin Cancer Res (2008) 14(20): 6674–82. doi: 10.1158/1078-0432.CCR-07-5212 18927310 · DOI · Paper page
  28. [31]Noguera-Troise I Daly C Papadopoulos NJ Coetzee S Boland P Gale NW. Blockade of Dll4 Inhibits Tumour Growth by Promoting Non-Productive Angiogenesis. Nature (2006) 444(7122): 1032. doi: 10.1038/nature05355 17183313 · DOI
  29. [32]Welford AF Biziato D Coffelt SB Nucera S Fisher M Pucci F. Tie2-Expressing Macrophages Limit the Therapeutic Efficacy of the Vascular-Disrupting Agent Combretastatin A4 Phosphate in Mice. J Clin Invest (2011) 121(5): 1969–73. doi: 10.1172/JCI44562 PMC3083764 21490397 · DOI
  30. [33]Huang J Soffer SZ Kim ES McCrudden KW Huang J New T. Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis11nih U10 Ca13539-27, Subcontract 6641 (Jk), Nih 1 R01 Ca08895101-A1 (Dy), Pediatric Cancer Foundation, and Sorkin Gift Fund. Note: J. Huang and Sz Soffer Contributed Equally to This Work. Mol Cancer Res (2004) 2(1): 36– 42. 14757844
  31. [34]Wu X Giobbie-Hurder A Liao X Connelly C Connolly E Li J. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunol Res (2017) 5(1): 17– 28. doi: 10.1158/2326-6066.Cir-16-0206 28003187 PMC5215959 · DOI · Paper page
  32. [36]Tobias J Steinberger P Drinić M Wiedermann U. Emerging Targets for Anticancer Vaccination: Pd-1. ESMO Open (2021) 6(5): 100278. doi: 10.1016/j.esmoop.2021.100278 34649221 PMC8517287 · DOI
  33. [37]Shin C Kim S Jo Y. Extending Traditional Antibody Therapies: Novel Discoveries in Immunotherapy and Clinical Applications. Mol Ther Oncolytics (2021) 22: 166–79. doi: 10.1016/j.omto.2021.08.005 PMC8416972 34514097 · DOI
  34. [38]Ohm J Carbone D. Vegf as a Mediator of Tumor-Associated Immunodeficiency. Immunol Res (2001) 23: 263–72. doi: 10.1385/ir:23:2-3:263 11444391 · DOI
  35. [39]Garber K. Promising Early Results for Immunotherapy-Antiangiogenesis Combination. J Natl Cancer Inst (2014) 106(11): dju392. doi: 10.1093/jnci/dju392 25421345 · DOI
  36. [40]Woo S Turnis M Goldberg M Bankoti J Selby M Nirschl C. Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-Cell Function to Promote Tumoral Immune Escape. Cancer Res (2012) 72(4): 917–27. doi: 10.1158/0008-5472.Can-11-1620 PMC3288154 22186141 · DOI · Paper page
  37. [42]Wallin J Bendell J Funke R Sznol M Korski K Jones S. Atezolizumab in Combination With Bevacizumab Enhances Antigen-Specific T-Cell Migration in Metastatic Renal Cell Carcinoma. Nat Commun (2016) 7: 12624. doi: 10.1038/ncomms12624 27571927 PMC5013615 · DOI
  38. [43]Huang Y Goel S Duda D Fukumura D Jain R. Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. Cancer Res (2013) 73(10): 2943–8. doi: 10.1158/0008-5472.Can-12-4354 PMC3655127 23440426 · DOI · Paper page
  39. [44]Hinshaw D Shevde L. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res (2019) 79(18): 4557–66. doi: 10.1158/0008-5472.Can-18-3962 PMC6744958 31350295 · DOI · Paper page
  40. [45]Khan K Kerbel R. Improving Immunotherapy Outcomes With Anti-Angiogenic Treatments and Vice Versa. Nat Rev Clin Oncol (2018) 15(5): 310–24. doi: 10.1038/nrclinonc.2018.9 29434333 · DOI
  41. [46]Soiffer R Hodi F Haluska F Jung K Gillessen S Singer S. Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma. J Clin Oncol: Off J Am Soc Clin Oncol (2003) 21(17): 3343–50. doi: 10.1200/jco.2003.07.005 12947071 · DOI
  42. [47]Dranoff G Jaffee E Lazenby A Golumbek P Levitsky H Brose K. Vaccination With Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity. Proc Natl Acad Sci USA (1993) 90(8): 3539–43. doi: 10.1073/pnas.90.8.3539 PMC46336 8097319 · DOI
  43. [48]Jaffee E Hruban R Biedrzycki B Laheru D Schepers K Sauter P. Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation. J Clin Oncol: Off J Am Soc Clin Oncol (2001) 19(1): 145–56. doi: 10.1200/jco.2001.19.1.145 11134207 · DOI
  44. [49]Nemunaitis J. Gvax (Gmcsf Gene Modified Tumor Vaccine) in Advanced Stage Non Small Cell Lung Cancer. J Control Release: Off J Control Release Soc (2003) 91: 225–31. doi: 10.1016/s0168-3659(03)00210-4 12932654 · DOI
  45. [50]Salgia R Lynch T Skarin A Lucca J Lynch C Jung K. Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-Small-Cell Lung Carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol (2003) 21(4): 624–30. doi: 10.1200/jco.2003.03.091 12586798 · DOI
  46. [51]Dikov M Ohm J Ray N Tchekneva E Burlison J Moghanaki D. Differential Roles of Vascular Endothelial Growth Factor Receptors 1 and 2 in Dendritic Cell Differentiation. J Immunol (Baltimore Md: 1950) (2005) 174(1): 215–22. doi: 10.4049/jimmunol.174.1.215 15611243 · DOI
  47. [52]Séguier S Tartour E Guérin C Couty L Lemitre M Lallement L. Inhibition of the Differentiation of Monocyte-Derived Dendritic Cells by Human Gingival Fibroblasts. PloS One (2013) 8(8): e70937. doi: 10.1371/journal.pone.0070937 23936476 PMC3732252 · DOI
  48. [53]Gabrilovich D Ishida T Oyama T Ran S Kravtsov V Nadaf S. Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages in Vivo: Presented in Part at the Keystone Symposium “Cellular and Molecular Biology of Dendritic Cells”, Santa Fe, Nm, March 3-9, 1998, and at the Annual Meeting of the American Association for Cancer Research, March 28-April 1, 1998. Blood (1998) 92(11): 4150–66. doi: 10.1182/blood.v92.11.4150 9834220 · DOI · Paper page
  49. [54]Gabrilovich DI Chen HL Girgis KR Cunningham HT Meny GM Nadaf S. Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells. Nat Med (1996) 2(10): 1096. doi: 10.1038/nm1096-1096 8837607 · DOI · Paper page
  50. [55]Ohm JE Gabrilovich DI Sempowski GD Kisseleva E Parman KS Nadaf S. Vegf Inhibits T-Cell Development and May Contribute to Tumor-Induced Immune Suppression. Blood (2003) 101(12): 4878–86. doi: 10.1182/blood-2002-07-1956 12586633 · DOI
  51. [56]Shi S Wang R Chen Y Song H Chen L Huang G. Combining Antiangiogenic Therapy With Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models. PloS One (2013) 8(6): e65757. doi: 10.1371/journal.pone.0065757 23799045 PMC3683034 · DOI
  52. [57]Meder L Schuldt P Thelen M Schmitt A Dietlein F Klein S. Combined Vegf and Pd-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res (2018) 78(15): 4270–81. doi: 10.1158/0008-5472.Can-17-2176 29776963 · DOI
  53. [58]Yasuda S Sho M Yamato I Yoshiji H Wakatsuki K Nishiwada S. Simultaneous Blockade of Programmed Death 1 and Vascular Endothelial Growth Factor Receptor 2 (Vegfr2) Induces Synergistic Anti-Tumour Effect in Vivo. Clin Exp Immunol (2013) 172(3): 500–6. doi: 10.1111/cei.12069 PMC3646450 23600839 · DOI
  54. [59]Gérard A Cope A Kemper C Alon R Köchl R. Lfa-1 in T Cell Priming, Differentiation, and Effector Functions. Trends Immunol (2021) 42(8): 706–22. doi: 10.1016/j.it.2021.06.004 PMC10734378 34266767 · DOI
  55. [60]Bouzin C Brouet A De Vriese J DeWever J Feron O. Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy. J Immunol (2007) 178(3): 1505–11. doi: 10.4049/jimmunol.178.3.1505 17237399 · DOI
  56. [61]Motz GT Santoro SP Wang L-P Garrabrant T Lastra RR Hagemann IS. Tumor Endothelium Fasl Establishes a Selective Immune Barrier Promoting Tolerance in Tumors. Nat Med (2014) 20(6): 607. doi: 10.1038/nm.3541 24793239 PMC4060245 · DOI
  57. [62]Ko JS Zea AH Rini BI Ireland JL Elson P Cohen P. Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients. Clin Cancer Res (2009) 15(6): 2148–57. doi: 10.1158/1078-0432.CCR-08-1332 19276286 · DOI
  58. [64]Terme M Pernot S Marcheteau E Sandoval F Benhamouda N Colussi O. Vegfa-Vegfr Pathway Blockade Inhibits Tumor-Induced Regulatory T-Cell Proliferation in Colorectal Cancer. Cancer Res (2013) 73(2): 539–49. doi: 10.1158/0008-5472.CAN-12-2325 23108136 · DOI · Paper page
  59. [65]Kwilas AR Ardiani A Donahue RN Aftab DT Hodge JW. Dual Effects of a Targeted Small-Molecule Inhibitor (Cabozantinib) on Immune-Mediated Killing of Tumor Cells and Immune Tumor Microenvironment Permissiveness When Combined With a Cancer Vaccine. J Trans Med (2014) 12(1): 294. doi: 10.1186/s12967-014-0294-y PMC4236498 25388653 · DOI
  60. [66]Li B Lalani A Harding T Luan B Koprivnikar K Huan Tu G. Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a Gm-Csf-Secreting Cancer Immunotherapy. Clin Cancer Res: An Off J Am Assoc Cancer Res (2006) 12(22): 6808–16. doi: 10.1158/1078-0432.Ccr-06-1558 17121902 · DOI
  61. [68]Mortara L Benest A Bates D Noonan D. Can the Co-Dependence of the Immune System and Angiogenesis Facilitate Pharmacological Targeting of Tumours? Curr Opin Pharmacol (2017) 35: 66– 74. doi: 10.1016/j.coph.2017.05.009 28623714 · DOI
  62. [69]Wu J Zhao X Sun Q Jiang Y Zhang W Luo J. Synergic Effect of Pd-1 Blockade and Endostar on the Pi3k/Akt/Mtor-Mediated Autophagy and Angiogenesis in Lewis Lung Carcinoma Mouse Model. Biomed Pharmacother = Biomed Pharmacother (2020) 125: 109746. doi: 10.1016/j.biopha.2019.109746 32106386 · DOI
  63. [71]Reck M Mok TSK Nishio M Jotte RM Cappuzzo F Orlandi F. Atezolizumab Plus Bevacizumab and Chemotherapy in Non-Small-Cell Lung Cancer (Impower150): Key Subgroup Analyses of Patients With Egfr Mutations or Baseline Liver Metastases in a Randomised, Open-Label Phase 3 Trial. Lancet Respir Med (2019) 7(5): 387– 401. doi: 10.1016/s2213-2600(19)30084-0 30922878 · DOI
  64. [72]Hellmann M Rizvi N Goldman J Gettinger S Borghaei H Brahmer J. Nivolumab Plus Ipilimumab as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer (Checkmate 012): Results of an Open-Label, Phase 1, Multicohort Study. Lancet Oncol (2017) 18(1): 31– 41. doi: 10.1016/s1470-2045(16)30624-6 27932067 PMC5476941 · DOI · Paper page
  65. [73]Rizvi N Antonia S. F Shepherd. Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (Bev) for Non-Small Cell Lung Cancer (Nsclc) Previously Treated With Chemotherapy: Metastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol• Biol• Phys (2014) 90(5): S32. doi: 10.1016/j.ijrobp.2014.08.206 · DOI
  66. [74]Herbst RS Arkenau H-T Santana-Davila R Calvo E Paz-Ares L Cassier PA. Ramucirumab Plus Pembrolizumab in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer, Gastro-Oesophageal Cancer, or Urothelial Carcinomas (Jvdf): A Multicohort, Non-Randomised, Open-Label, Phase 1a/B Trial. Lancet Oncol (2019) 20(8): 1109–23. doi: 10.1016/s1470-2045(19)30458-9 31301962 · DOI
  67. [75]Bang YJ Golan T Dahan L Fu S Moreno V Park K. Ramucirumab and Durvalumab for Previously Treated, Advanced Non-Small-Cell Lung Cancer, Gastric/Gastro-Oesophageal Junction Adenocarcinoma, or Hepatocellular Carcinoma: An Open-Label, Phase Ia/B Study (Jvdj). Eur J Cancer (2020) 137: 272–84. doi: 10.1016/j.ejca.2020.06.007 32827847 · DOI
  68. [76]McDermott DF Huseni MA Atkins MB Motzer RJ Rini BI Escudier B. Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination With Bevacizumab Versus Sunitinib in Renal Cell Carcinoma. Nat Med (2018) 24(6): 749–57. doi: 10.1038/s41591-018-0053-3 PMC6721896 29867230 · DOI · Paper page
  69. [77]Chambers A Kundranda M Rao S Mahmoud F Niu J. Anti-Angiogenesis Revisited: Combination With Immunotherapy in Solid Tumors. Curr Oncol Rep (2021) 23(9): 100. doi: 10.1007/s11912-021-01099-7 34269922 · DOI
  70. [79]Choueiri TK Larkin J Oya M Thistlethwaite F Martignoni M Nathan P. Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients With Advanced Clear-Cell Renal-Cell Carcinoma (Javelin Renal 100): An Open-Label, Dose-Finding and Dose-Expansion, Phase 1b Trial. Lancet Oncol (2018) 19(4): 451–60. doi: 10.1016/s1470-2045(18)30107-4 29530667 · DOI · Paper page
  71. [80]Motzer RJ Penkov K Haanen J Rini B Albiges L Campbell MT. Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med (2019) 380(12): 1103–15. doi: 10.1056/NEJMoa1816047 PMC6716603 30779531 · DOI
  72. [81]Grimm MO Leucht K Grunwald V Foller S. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients With Pd-1 or Pd-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. J Clin Med (2020) 9(2): 565. doi: 10.3390/jcm9020565 PMC7074019 32092974 · DOI
  73. [82]Albiges L Barthelemy P Gross-Goupil M Negrier S Needle MN Escudier B. Tinivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients With Metastatic Renal Cell Carcinoma. Ann Oncol (2021) 32(1): 97– 102. doi: 10.1016/j.annonc.2020.09.021 33010459 · DOI
  74. [84]Lee MS Ryoo B-Y Hsu C-H Numata K Stein S Verret W. Atezolizumab With or Without Bevacizumab in Unresectable Hepatocellular Carcinoma (Go30140): An Open-Label, Multicentre, Phase 1b Study. Lancet Oncol (2020) 21(6): 808–20. doi: 10.1016/s1470-2045(20)30156-x 32502443 · DOI · Paper page
  75. [86]Finn RS Ikeda M Zhu AX Sung MW Baron AD. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol (2020) 38(26): 2960–70. doi: 10.1200/JCO.20.00808 PMC7479760 32716739 · DOI · Paper page
  76. [87]Galle PR Finn RS Qin S Ikeda M Zhu AX Kim T-Y. Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (Imbrave150): An Open-Label, Randomised, Phase 3 Trial. Lancet Oncol (2021) 22(7): 991– 1001. doi: 10.1016/s1470-2045(21)00151-0 34051880 · DOI
  77. [88]Ferrucci PF Minchella I Mosconi M Gandini S Verrecchia F Cocorocchio E. Dacarbazine in Combination With Bevacizumab for the Treatment of Unresectable/Metastatic Melanoma: A Phase II Study. Melanoma Res (2015) 25(3): 239–45. doi: 10.1097/CMR.0000000000000146 25746039 · DOI
  78. [89]Wu X Giobbie-Hurder A Liao X Lawrence D McDermott D Zhou J. Vegf Neutralization Plus Ctla-4 Blockade Alters Soluble and Cellular Factors Associated With Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Cancer Immunol Res (2016) 4(10): 858–68. doi: 10.1158/2326-6066.CIR-16-0084 PMC5050160 27549123 · DOI
  79. [92]Damato A Berselli A Iachetta F Romagnani A Larocca M Arias AG. Preliminary Safety Analysis of Phase Ii Open-Label Nivacor Trial (Goirc-03-2018) in Patients With Advanced Colorectal Cancer Ras or Braf Mutated. J Clin Oncol (2021) 39: 37. doi: 10.1200/jco.2021.39.3_suppl.37 · DOI
  80. [93]Ramjiawan RR Griffioen AW Duda DG. Anti-Angiogenesis for Cancer Revisited: Is There a Role for Combinations With Immunotherapy? Angiogenesis (2017) 20(2): 185– 204. doi: 10.1007/s10456-017-9552-y 28361267 PMC5439974 · DOI
  81. [94]Jain RK. Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell (2014) 26(5): 605–22. doi: 10.1016/j.ccell.2014.10.006 PMC4269830 25517747 · DOI · Paper page
  82. [95]des Guetz G Uzzan B Chouahnia K Morère J. Cardiovascular Toxicity of Anti-Angiogenic Drugs. Target Oncol (2011) 6(4): 197– 202. doi: 10.1007/s11523-011-0204-7 22116787 · DOI

Cited by

Sorted by citations

Authors
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J.
Affiliations
  • University of Electronic Science and Technology of China (CN)
  • Capital Medical University (CN)
  • Sichuan University (CN)
  • Southwest Medical University (CN)
  • Mianyang Third People's Hospital (CN)
Corresponding author
  • Luo, Feng
  • He, Jun
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2022-02-23
Volume
13
Pages
802846-802846
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2022.802846
PMC
PMC8905241
OpenAlex
W4214681573
Cited by
117
References
13
Citations by year
2026: 13 · 2025: 20 · 2024: 31 · 2023: 36 · 2022: 17
FWCI
2.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
anti-angiogenic therapy, cancer immunotherapy, tumor microenvironment, drug resistance, combination therapy, synergistic antitumor effect, biomarkers, non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, breast cancer, glioblastoma, pancreatic ductal adenocarcinoma
MeSH terms
Carcinoma, Non-Small-Cell Lung, Humans, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Angiogenesis Inhibitors, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review